Navigation Links
Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions
Date:5/8/2008

s Voltaren(R) (single dose), 1214 plus or minus 750ng/mL. Area under the plasma concentration curve (AUC) for zero to 12 hours was FLECTOR(R) Patch at 15.2 plus or minus 6.9ng*h/mL versus Voltaren(R), 1754 plus or minus 1060 ng*h/mL. The dose-adjusted relative percent bioavailability of diclofenac after treatment with FLECTOR(R) Patch versus Voltaren(R) was 0.7 plus or minus 0.4 (i.e., <1 percent). The study was supported by a grant from Alpharma Pharmaceuticals LLC.

About FLECTOR(R) Patch

Each FLECTOR(R) Patch measures approximately 4 inches by 5.5 inches and contains 180-mg of diclofenac epolamine, which has demonstrated both anti-inflammatory and analgesic (pain-relieving) activities. The recommended dose of FLECTOR(R) Patch is one patch to the most painful area twice a day (12 hours at a time). FLECTOR(R) Patch should be applied to intact or non-damaged skin.

Although the prescribing information does not specify a limit on the duration of use for FLECTOR(R) Patch, it recommends that FLECTOR(R) Patch be used at the lowest effective dose for the shortest duration consistent with individual patient treatment goals.

FLECTOR(R) Patch delivers significant pain relief with rates of common adverse events with FLECTOR(R) Patch similar to placebo patch observed in clinical trials for up to two weeks with approximately 600 patients. In addition, the incidence of gastrointestinal side effects such as nausea and upset stomach were comparable to placebo patch.

In the clinical trials, 3 percent of patients in both the FLECTOR(R) Patch and placebo patch groups discontinued treatment due to an adverse event. The most common adverse events leading to discontinuation were application site reactions, occurring in 2 percent of both the FLECTOR(R) Patch group and the placebo patch group.

Outside the U.S., the diclofenac patch has an extensive track record of safety, having been introduced in Switzerland in 1993, and is currently approved in 4
'/>"/>

SOURCE Alpharma Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months
2. Genetic Immunity Announces Data Related to the DermaVir Nanomedicine Patch in the Journal of Immunology
3. Iomai Receives HHS Approval to Begin Phase 2 Trial of H5N1 Influenza Adjuvant Patch
4. Iomai and Merck & Co., Inc. Evaluate Use of Iomai Immunostimulant Patch
5. Genetic Immunity Presents Clinical Data on DermaVir Patch Immune Therapy at 15th Annual Conference on Retroviruses and Opportunistic Infections
6. Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain
7. Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system)
8. Cerimon Pharmaceuticals Initiates Phase I Clinical Study of Topical Diclofenac Sodium Patch
9. Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
10. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
11. Use of PressureWire(R) Yields a More Accurate Assessment of Translesion Pressure Gradients in Peripheral Vasculature, Two New Studies Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... -- RealMed has been ranked the #1 ... 2009 Top 20 Best in KLAS Awards: ... is a dynamic revenue cycle management solution ... healthcare providers and all payers. ... in vendor performance measurement in the software, ...
(Date:12/16/2009)... Greenway Medical Technologies, Inc. today announced that its ... management and interoperability solution, Prime Suite® 2011, ... annual 2009 Top 20 Best in KLAS ... ,, For practices having between six and 25 ... in KLAS in ambulatory EMR for the fourth ...
(Date:12/16/2009)... N.J. and ANN ARBOR, Mich., Dec. 16 /PRNewswire-FirstCall/ ... ) and NanoBio Corporation today announced an exclusive ... for the over-the-counter (OTC) use of NB-001, a ... the treatment of cold sores. Developed by NanoBio, ... that causes cold sores, herpes labialis . ...
Breaking Medicine Technology:RealMed Ranked as 2009 'Best in KLAS' Claims and Clearinghouse Service 2RealMed Ranked as 2009 'Best in KLAS' Claims and Clearinghouse Service 3Greenway Medical Technologies' PrimeSuite Wins Three Best in KLAS Awards 2Greenway Medical Technologies' PrimeSuite Wins Three Best in KLAS Awards 3Greenway Medical Technologies' PrimeSuite Wins Three Best in KLAS Awards 4GlaxoSmithKline and NanoBio Announce OTC Licensing Agreement for Cold Sore Treatment 2Booshoot Founder 26amp 3B CEO Jackie Heinricher Honored as Visionary Entrepreneur by Martha Stewart 14412 1Booshoot Founder 26amp 3B CEO Jackie Heinricher Honored as Visionary Entrepreneur by Martha Stewart 14412 2Pieris Reports Preclinical Development Progress of its Next Generation VEGF Antagonist 14410 1Pieris Reports Preclinical Development Progress of its Next Generation VEGF Antagonist 14410 2Pieris Reports Preclinical Development Progress of its Next Generation VEGF Antagonist 14410 3Kansas Bioscience Authority Commits 2450 Million to Increase Venture Capital Accelerate Bioscience Business Growth 14408 1Kansas Bioscience Authority Commits 2450 Million to Increase Venture Capital Accelerate Bioscience Business Growth 14408 2Kansas Bioscience Authority Commits 2450 Million to Increase Venture Capital Accelerate Bioscience Business Growth 14408 3
... the "NEXT" Study Also Showed Arzoxifene Significantly Suppressed ... with OsteoporosisATHENS, Greece, March 23 Eli Lilly ... new data showing arzoxifene, an investigational selective estrogen ... increasing bone mineral density (BMD) in the lumbar ...
... Calif., March 19 Oxygen Biotherapeutics, Inc. (OTC Bulletin ... a letter from the FDA that outlines what the ... resume clinical studies of Oxycyte(R) in TBI. Oxycyte is ... in response to the company,s request for formal dispute ...
Other Medicine Technology:Phase III Trial Showed Investigational Compound Arzoxifene Was Superior to Evista(R) (raloxifene HCl) in Increasing BMD in Postmenopausal Women with Osteoporosis 2Phase III Trial Showed Investigational Compound Arzoxifene Was Superior to Evista(R) (raloxifene HCl) in Increasing BMD in Postmenopausal Women with Osteoporosis 3Phase III Trial Showed Investigational Compound Arzoxifene Was Superior to Evista(R) (raloxifene HCl) in Increasing BMD in Postmenopausal Women with Osteoporosis 4Phase III Trial Showed Investigational Compound Arzoxifene Was Superior to Evista(R) (raloxifene HCl) in Increasing BMD in Postmenopausal Women with Osteoporosis 5Oxygen Biotherapeutics, Inc. Receives Letter From FDA Outlining Path Forward to Resume Oxycyte Clinical Trials in TBI in U.S.A. 2Oxygen Biotherapeutics, Inc. Receives Letter From FDA Outlining Path Forward to Resume Oxycyte Clinical Trials in TBI in U.S.A. 3
(Date:12/16/2009)... Ensure and Encourage Access to Quality, Cost-Effective Care , ... ... of Congress have debated the best ways to rein in runaway ... reform. An important part of the ongoing discussion includes how ... care providers besides doctors of medicine (MDs) or osteopathy (DOs). ...
(Date:12/16/2009)... leader of Digital Pen and Paper technology and the provider ... today announced that it is ranked among the Fastest Growing ... 2009. , ... (PRWEB) December 16, ... for the capture, digitalization and management of handwritten data. Kayentis ...
(Date:12/16/2009)... expert says, , , WEDNESDAY, Dec. 16 (HealthDay News) -- ... to die when they receive an implantable cardioverter defibrillator, ... people, ages 65 to 85, who were eligible for ... measure of the heart,s pumping ability) of 35 percent ... were treated with standard medication and an implanted defibrillator ...
(Date:12/16/2009)... Shoppers like knowing if their salad ... But grocers have found it burdensome to implement ... requiring them to provide the information at point ... easyCOOLnow.com for easily making grocery and produce ... that require retailers of unprocessed fruits, vegetables and ...
(Date:12/16/2009)... A new software program developed by CareRise ... facilities to calculate their staffing needs as it relates ... allows inpatient healthcare facilities to calculate their mandatory nurse-to-patient ... and receive a daily report as to how it ... leader in risk management in the healthcare industry, has ...
Breaking Medicine News(10 mins):Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 2Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 3Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 4Health News:Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs 5Health News:With a Revenue Growth of Over 500% During the Last 5 Years, Kayentis is Ranked on the Deloitte Technology Fast 500 -- EMEA 2009 2Health News:Implanted Defibrillator Might Extend Life 2Health News:New Website Helps Grocers Comply With COOL Laws 2Health News:United States Patent Office Allows CareRise Patent on 24/7 Staff-Census Software 2
... An outbreak of hand, foot-and-mouth disease in eastern Sarawak state ... are saying that they would shut down all schools in ... country. // ,The virus, which causes the disease, ... four have even succumbed to it. "In peninsular Malaysia, the ...
... has receded and with no new case cropped up in ... serve chicken dishes on board.// ,The usual favourites ... toast were sighted on many flights Wednesday morning. ... back on the list," said Sunil Taneja, director business development, ...
... advancements have had the potential to revolutionize diverse areas// ... The Internet has indeed made the world a smaller ... has been a parallel increase in the incidence of ... of late become a playground that allows people to ...
... to Multidrug Resistant Staphylococcus aureus (MRSA) in the northwest has ... undergo a surgery due to this infection. On such ... refuses to be operated due to the fear of acquiring ... Yorks, to be treated privately because of the high risk ...
... A new study has now raised the possibility of ... increased risk of breast cancer//. Salts of metals like ... on breast cancer cells, leading to malignant transformation. ... found to accelerate the growth of breast cancer cell ...
... children in Ecuador whose mothers were exposed to pesticides while ... copy geometric figures as compared to a control group. This ... issue of Paediatrics. ,Philippe Grandjean, ... led a team of researchers and analyzed data on 72 ...
Other Medicine News:Health News:Cyber Sex, No Longer A Fantasy Of The Mind 2Health News:Aluminum Salts In Underarm Deodorants Increase Risk Of Breast Cancer 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: